Bioverativ Inc Stock

Stocks

18-04-27	Sanofi : sees new acquisitions and drugs reviving growth	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-02-15	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
18-02-07	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
18-01-29	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
18-01-22	Stocks hit record as senators reach deal to end shutdown	RE
18-01-22	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
18-01-22	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
18-01-22	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

18-03-06	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
18-02-14	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
18-02-13	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
18-01-24	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
18-01-24	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

18-03-28	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
18-03-08	Sanofi finalise l'acquisition de Bioverativ
18-03-08	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
18-02-23	Sanofi : franchit une étape dans son offre sur Bioverativ
18-02-07	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy J.R. Harris PRN	Corporate Officer/Principal	-	-
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	2018-03-07
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
WUXI APPTEC CO., LTD.	-0.25%	-0.92%	+49.47%	+89.45%	68.13B
ARGENX SE	+1.21%	+2.55%	+46.72%	+90.66%	63.6B
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	+1.81%	+49.04%	+12.07%	25.57B
INSMED INCORPORATED	-0.25%	-1.99%	-10.72%	+455.09%	26.6B
BIONTECH SE	+0.33%	-9.64%	+1.95%	-15.70%	25.52B
PHARMAESSENTIA CORPORATION	-6.09%	-11.19%	+224.80%	+351.08%	18.23B
GENMAB A/S	+1.18%	+1.66%	+35.20%	-18.67%	19.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.35%	+7.84%	+540.26%	15.16B
EXELIXIS, INC.	+4.12%	+4.29%	+52.03%	+154.09%	13.54B
Average	+0.01%	-3.84%	+50.70%	+184.26%	30.67B
Weighted average by Cap.	+0.15%	-2.87%	+47.00%	+145.57%

Employees

Sector